News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
241,379 Results
Type
Article (10638)
Company Profile (120)
Press Release (230615)
Multimedia
Podcasts (84)
Webinars (12)
Section
Business (78195)
Career Advice (1096)
Deals (13425)
Drug Delivery (48)
Drug Development (37272)
Employer Resources (93)
FDA (4152)
Job Trends (5499)
News (131132)
Policy (9942)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (597)
Accelerated approval (8)
Adcomms (5)
Allergies (59)
Alliances (15727)
ALS (73)
Alzheimer's disease (662)
Antibody-drug conjugate (ADC) (146)
Approvals (4334)
Artificial intelligence (202)
Autoimmune disease (68)
Automation (22)
Bankruptcy (98)
Best Places to Work (4304)
BIOSECURE Act (16)
Biosimilars (113)
Biotechnology (79)
Bladder cancer (50)
Brain cancer (25)
Breast cancer (181)
Cancer (1850)
Cardiovascular disease (125)
Career advice (937)
Career pathing (33)
CAR-T (128)
CDC (17)
Cell therapy (317)
Cervical cancer (9)
Clinical research (32758)
Collaboration (718)
Compensation (653)
Complete response letters (25)
COVID-19 (1188)
CRISPR (28)
C-suite (455)
Cystic fibrosis (45)
Data (2725)
Decentralized trials (2)
Denatured (14)
Depression (74)
Diabetes (154)
Diagnostics (1667)
Digital health (12)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (82)
Drug pricing (78)
Drug shortages (6)
Duchenne muscular dystrophy (99)
Earnings (42130)
Editorial (40)
Employer branding (12)
Employer resources (78)
Events (41411)
Executive appointments (532)
FDA (5629)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (8)
Funding (597)
Gene editing (63)
Generative AI (21)
Gene therapy (222)
GLP-1 (394)
Government (1464)
Grass and pollen (2)
Guidances (302)
Healthcare (4515)
HIV (44)
Huntington's disease (16)
IgA nephropathy (33)
Immunology and inflammation (117)
Immuno-oncology (36)
Indications (45)
Infectious disease (1328)
Inflammatory bowel disease (76)
Inflation Reduction Act (10)
Influenza (53)
Intellectual property (115)
Interviews (345)
IPO (8135)
IRA (20)
Job creations (1283)
Job search strategy (674)
JPM (42)
Kidney cancer (9)
Labor market (76)
Layoffs (217)
Leadership (33)
Legal (1334)
Liver cancer (37)
Longevity (4)
Lung cancer (285)
Lymphoma (147)
Machine learning (17)
Management (31)
Manufacturing (425)
MASH (109)
Medical device (2549)
Medtech (2563)
Mergers & acquisitions (5848)
Metabolic disorders (522)
Multiple sclerosis (87)
NASH (8)
Neurodegenerative disease (123)
Neuropsychiatric disorders (41)
Neuroscience (1208)
NextGen: Class of 2026 (1611)
Non-profit (661)
Now hiring (52)
Obesity (246)
Opinion (210)
Ovarian cancer (55)
Pain (74)
Pancreatic cancer (84)
Parkinson's disease (99)
Partnered (13)
Patents (195)
Patient recruitment (215)
Peanut (24)
People (22058)
Pharmaceutical (40)
Pharmacy benefit managers (10)
Phase 1 (9762)
Phase 2 (15014)
Phase 3 (11256)
Pipeline (2949)
Policy (147)
Postmarket research (635)
Preclinical (3784)
Press Release (23)
Prostate cancer (82)
Psychedelics (25)
Radiopharmaceuticals (148)
Rare diseases (346)
Real estate (1642)
Recruiting (40)
Regulatory (9041)
Reports (34)
Research institute (505)
Resumes & cover letters (128)
Rett syndrome (3)
RNA editing (5)
RSV (32)
Schizophrenia (104)
Series A (98)
Series B (68)
Service/supplier (4)
Sickle cell disease (36)
Special edition (24)
Spinal muscular atrophy (63)
Sponsored (11)
Startups (1223)
State (1)
Stomach cancer (2)
Supply chain (44)
Tariffs (60)
The Weekly (69)
Vaccines (464)
Venture capital (55)
Weight loss (123)
Women's health (29)
Worklife (17)
Date
Today (24)
Last 7 days (238)
Last 30 days (894)
Last 365 days (14486)
2026 (1316)
2025 (14580)
2024 (16348)
2023 (18660)
2022 (21353)
2021 (23405)
2020 (21076)
2019 (14562)
2018 (10723)
2017 (11840)
2016 (9893)
2015 (12486)
2014 (9244)
2013 (6663)
2012 (6891)
2011 (6994)
2010 (6551)
Location
Africa (321)
Alabama (30)
Alaska (1)
Arizona (57)
Arkansas (2)
Asia (17353)
Australia (2361)
California (5328)
Canada (1408)
China (763)
Colorado (225)
Connecticut (231)
Delaware (207)
Europe (34418)
Florida (808)
Georgia (172)
Hawaii (1)
Idaho (10)
Illinois (304)
India (27)
Indiana (199)
Iowa (14)
Japan (187)
Kansas (74)
Kentucky (16)
Louisiana (13)
Maine (26)
Maryland (618)
Massachusetts (4056)
Michigan (119)
Minnesota (191)
Mississippi (2)
Missouri (49)
Montana (11)
Nebraska (8)
Nevada (30)
New Hampshire (19)
New Jersey (1583)
New Mexico (14)
New York (1619)
North Carolina (689)
Northern California (2739)
Ohio (141)
Oklahoma (7)
Oregon (16)
Pennsylvania (1004)
Puerto Rico (12)
Rhode Island (16)
South America (414)
South Carolina (26)
Southern California (2078)
Tennessee (28)
Texas (679)
United States (18726)
Utah (136)
Virginia (122)
Washington D.C. (28)
Washington State (396)
West Virginia (1)
Wisconsin (35)
Wyoming (2)
241,379 Results for "prep biopharm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Infectious disease
Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the heels of the landmark Yeztugo approval.
July 15, 2025
·
4 min read
·
Tristan Manalac
Earnings
Gilead Confident in PrEP Franchise Even Amid Preventive Task Force Uncertainties
The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV PrEP Yeztugo—that insurers must cover. A recently postponed meeting has raised concerns that Health Secretary RFK Jr. could abolish or overhaul the group.
August 8, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Enlil Introduces the Industry’s First Evidence-Based Milestone View for Medical Device Companies to Streamline Development Phases and FDA eSTAR Prep
February 4, 2026
·
5 min read
Press Releases
Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research
December 4, 2025
·
4 min read
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.
July 2, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing
October 17, 2025
·
4 min read
Press Releases
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets
October 15, 2025
·
5 min read
Press Releases
PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
October 8, 2025
·
5 min read
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
Shanghai-based LaNova Medicines—which has captured the attention of some of the biggest Western pharmas—will be folded into fellow Chinese company Sino Biopharmaceutical in a deal worth up to $951 million.
July 16, 2025
·
1 min read
·
Tristan Manalac
Press Releases
QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025
September 18, 2025
·
6 min read
1 of 24,138
Next